• Email
  • Help

Questions & Answers

On 28 June 2018, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing authorisation for the medicinal product Yescarta, intended for the treatment of diffuse large cell lymphoma (DLBCL) and primary mediastinal B-cell lymphoma (PMBCL). As Yescarta is an advanced therapy medicinal product, the CHMP positive opinion is based on an assessment by the Committee for Advanced Therapies.

Yescarta, which was designated as an orphan medicinal product on 16 December 2014, was reviewed under EMA’s accelerated assessment programme. The applicant for this medicinal product is Kite Pharma EU B.V.

Yescarta will be available as a dispersion for infusion. The active substance of Yescarta is axicabtagene ciloleucel, an autologous, immunocellular cancer therapy which involves reprogramming a patient’s own T cells to identify and eliminate CD19-expressing cells. This is achieved by addition of a transgene encoding a chimeric antigen receptor (CAR).

The benefits with Yescarta are its ability to achieve an objective response with a significant duration in patients with DLBCL and patients with PMBCL. The most common side effects are cytokine release syndrome, infections, pyrexia, diarrhoea, nausea, hypotension and fatigue.

The full indication is:

'Yescarta is indicated for the treatment of adult patients with relapsed or refractory diffuse large B‑cell lymphoma (DLBCL) and primary mediastinal large B‑cell lymphoma (PMBCL), after two or more lines of systemic therapy.'

It is proposed that Yescarta be administered in a qualified treatment centre. Therapy should be started and supervised by a healthcare professional experienced in the treatment of haematological malignancies and trained for administration and management of patients treated with Yescarta.

Detailed recommendations for the use of this product will be described in the summary of product characteristics (SmPC), which will be published in the European public assessment report (EPAR) and made available in all official European Union languages after the marketing authorisation has been granted by the European Commission.

Name Language First published Last updated
CHMP summary of positive opinion for Yescarta (English only) 2018-06-29  

Key facts

Product details for Yescarta
INN or common name

axicabtagene ciloleucel

Therapeutic area Lymphoma, Large B-Cell, DiffuseLymphoma, Follicular
Active substance

axicabtagene ciloleucel

Date opinion adopted28/06/2018
Company name

Kite Pharma EU B.V.

Application typeInitial authorisation